Andere Sprachen LakeShore Biopharma Co., Ltd

Aktien

A3D4XP

KYG9845F1090

LSB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 24.06.2024			% 5 Tage	% 1. Jan.
0.6545 ^USD	+9.08%		-5.16%	+28.08%

18.06.	LakeShore Biopharma Co., Ltd gibt Rücktritt von Zengjun Xu als Direktor bekannt	CI
10.06.	Lakeshore Biopharma Co. Ltd. gibt Veränderungen in der Geschäftsführung bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

LakeShore Biopharma : Resignation of Ms. Chunyuan Wu (Brenda) Form 6 K	19.06.
LakeShore Biopharma Co., Ltd Announces Chief Financial Officer Changes	18.06.
LakeShore Biopharma Co., Ltd Announces Resignation of Zengjun Xu as Director	18.06.
LakeShore Biopharma : Departure of Directors Form 6 K	10.06.
Lakeshore Biopharma Co., Ltd Announces Executive Changes	10.06.
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS	28.05.
YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28	24.05.
YS Biopharma Announces Name Change to LakeShore Biopharma	24.05.
YS Biopharma Announces Results of Extraordinary General Meeting	21.05.
YS Biopharma Co., Ltd. Approves Board Appointments	21.05.
YS Biopharma Co., Ltd. has Changed its Name to LakeShore Biopharma Co., Ltd	21.05.
Ys Biopharma Co., Ltd Announces Executive Changes	07.05.
YS Biopharma Co., Ltd. Approves the Appointment of Hui Shao as the Chief Business Officer	07.05.
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer	07.05.
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule	29.04.
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024	22.04.
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023	19.04.
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024	19.04.
YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment	18.04.
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine	18.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen LakeShore Biopharma Co., Ltd

Aktien

A3D4XP

KYG9845F1090

LSB

Andere Sprachen

Filter